建立心血管疾病预防投资的经济论据。 - Suppr | 超能文献

Building the Economic Case for Investment in Cardiovascular Prevention.

作者信息

Kazi Dhruv S

机构信息

Department of Medicine, Department of Epidemiology and Biostatistics, Center for Vulnerable Populations, and the Philip R. Lee Institute of Health Policy Studies, University of California San Francisco, San Francisco, California; and the Division of Cardiology, Zuckerberg San Francisco General Hospital, San Francisco, California.

出版信息

J Am Coll Cardiol. 2018 Mar 13;71(10):1090-1093. doi: 10.1016/j.jacc.2018.01.022.

DOI:10.1016/j.jacc.2018.01.022

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Building the Economic Case for Investment in Cardiovascular Prevention.建立心血管疾病预防投资的经济论据。

J Am Coll Cardiol. 2018 Mar 13;71(10):1090-1093. doi: 10.1016/j.jacc.2018.01.022.

2

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics.评估心血管治疗价值中的经济学与成本效益。评估心血管治疗方法的经济影响。

Am Heart J. 1999 May;137(5):S35-7. doi: 10.1016/s0002-8703(99)70425-4.

3

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Fundamentals of economic analysis.评估心血管治疗价值中的经济学与成本效益。经济分析基础。

Am Heart J. 1999 May;137(5):S38-40. doi: 10.1016/s0002-8703(99)70426-6.

4

A novel cost-effectiveness model of prescription eicosapentaenoic acid extrapolated to secondary prevention of cardiovascular diseases in the United States.一种新型的处方二十碳五烯酸成本效益模型，该模型已外推至美国心血管疾病的二级预防。

J Med Econ. 2016 Oct;19(10):1003-10. doi: 10.1080/13696998.2016.1207652. Epub 2016 Jul 15.

5

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis.评估心血管治疗价值中的经济学与成本效益。成本效益分析中的统计学问题。

Am Heart J. 1999 May;137(5):S47-50. doi: 10.1016/s0002-8703(99)70428-x.

6

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials.评估心血管治疗价值中的经济学与成本效益。经济模型在随机临床试验中的作用。

Am Heart J. 1999 May;137(5):S41-6. doi: 10.1016/s0002-8703(99)70427-8.

7

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful economic study? The health systems perspective.评估心血管治疗价值中的经济学与成本效益。什么构成一项有用的经济学研究？卫生系统视角。

Am Heart J. 1999 May;137(5):S67-70. doi: 10.1016/s0002-8703(99)70432-1.

8

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data.评估心血管治疗价值中的经济学与成本效益。阿昔单抗的应用：比较经济数据。

Am Heart J. 1999 May;137(5):S123-5. doi: 10.1016/s0002-8703(99)70445-x.

9

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.评估心血管治疗价值中的经济学与成本效益。降脂药物、成本效益数据与处方集系统：卫生系统视角。

Am Heart J. 1999 May;137(5):S111-4. doi: 10.1016/s0002-8703(99)70442-4.

10

Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. A survey of standards and guidelines for cost-effectiveness analysis in health care.评估心血管治疗价值中的经济学与成本效益。医疗保健成本效益分析的标准与指南调查。

Am Heart J. 1999 May;137(5):S53-61. doi: 10.1016/s0002-8703(99)70430-8.

引用本文的文献

1

The adverse effect of mood swings on the risk of cardiovascular diseases: Evidence from Mendelian randomization analysis.情绪波动对心血管疾病风险的不良影响：来自孟德尔随机化分析的证据。

Medicine (Baltimore). 2024 Dec 20;103(51):e41003. doi: 10.1097/MD.0000000000041003.

2

Validation of the Sleep Regularity Index in Older Adults and Associations with Cardiometabolic Risk.老年人睡眠规律指数的验证及其与心血管代谢风险的关联。

Sci Rep. 2018 Sep 21;8(1):14158. doi: 10.1038/s41598-018-32402-5.